Having high cholesterol (hyperlipidemia) is a risk factor for cardiovascular disease. Many people with hyperlipidemia take a type of medication called a statin, such as Lipitor (atorvastatin). For some, a statin is well-tolerated and effective in lowering cholesterol (lipid) levels. Others may take a high dose of a statin and still develop cardiovascular disease—or may not be able to tolerate a statin medication at all.
In 2015, the U.S. Food and Drug Administration (FDA) approved two injectable prescription drugs that lower LDL cholesterol and prevent cardiovascular events. The drugs—Repatha and Praluent—are classified as PCSK9 inhibitors. PCSK9 inhibitors work differently than statins. They can be used alone or in combination with a statin. Amgen, Inc. makes Repatha and Regeneron Pharmaceuticals, Inc. makes Praluent.
This article will discuss the uses, side effects, and safety information of PCSK9 inhibitors. The table below lists the two currently available PCSK9 inhibitors.
Drug name | Learn more | See SingleCare price |
---|---|---|
Praluent | praluent details | praluent price |
Repatha | repatha details | repatha price |
Repatha Sureclick | repatha-sureclick details | repatha-sureclick price |
PCSK9 inhibitors are prescription medications that are injected under the skin (subcutaneously), used to lower low-density lipoprotein cholesterol levels (LDL-C levels) and lower the risk of cardiovascular events. A PCSK9 inhibitor may be prescribed to patients who have genetic hyperlipidemia or who are at very high risk for cardiovascular disease (heart disease) and cannot tolerate statins, or when high-dose statins are not effective enough.
PCSK9 inhibitors are monoclonal antibodies. A monoclonal antibody is made in a lab and can bind to a substance.
PCSK9 inhibitors bind to proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 binds to low-density lipoprotein receptors (LDL receptors, or LDLR) on the surface of liver cells (hepatocytes). This PCSK9 inhibition increases the number of LDLRs that can clear LDL and thereby lowers LDL cholesterol (LDL-C) levels.
Praluent was studied in the ODYSSEY OUTCOMES trial. This trial studied the safety and efficacy of Praluent compared with placebo in patients with recent acute coronary syndrome (ACS) who were already on high-dose/maximum-tolerated statin therapy.
The trial showed that Praluent, taken every other week, significantly decreased ischemic events, including heart attack (myocardial infarction) and death, compared with placebo, in patients with a recent (past 1-12 months) acute coronary syndrome event. Praluent also reduced first events and total nonfatal events.
Repatha was studied in the FOURIER trial. This trial studied the safety and efficacy of Repatha in high-risk patients taking statins. The study concluded that Repatha was effective, compared to placebo, at reducing cardiovascular events. Repatha significantly lowered LDL cholesterol levels. This study did not find a benefit in regards to mortality.
PCSK9 inhibitors are injectable medications indicated:
To lower LDL cholesterol (along with diet, alone or combined with other LDL cholesterol-lowering medications) in adults with primary hyperlipidemia (high cholesterol caused by genetics), including heterozygous familial hypercholesterolemia.
To lower LDL cholesterol (along with other LDL cholesterol-lowering medications) in patients with homozygous familial hypercholesterolemia.
In adults with cardiovascular disease to lower the risk of cardiovascular events such as heart attack and stroke.
Before taking a PCSK9 inhibitor, tell your doctor about all of your medical conditions and medical history. Tell your doctor about all of the medications you take, including prescription drugs, over-the-counter (OTC) medicines, and vitamins or supplements.
Men can take a PCSK9 inhibitor, provided they fit into one of the indications, and the doctor determines a PCSK9 inhibitor will be safe and appropriate.
Women who are not pregnant or breastfeeding can take a PCSK9 inhibitor, provided they fit into one of the indications and prescribed by their doctor.
Praluent and Repatha have not been studied enough to determine safety in pregnancy. However, they have the potential to be transmitted to the developing unborn baby. There is no information regarding PCSK9 inhibitors and breastfeeding.
Consult your healthcare professional for medical advice on PCSK9 inhibitors and pregnancy and/or breastfeeding.
Praluent has not been studied for safety and efficacy in children.
Repatha may be used in patients ages 13 years and older, along with diet and other LDL lowering medication to treat homozygous familial hypercholesterolemia.
Clinical trials for both Praluent and Repatha did not find a difference in safety or efficacy based on age. However, the prescribing information for both PCSK9 inhibitors states that “greater sensitivity of some older individuals cannot be ruled out.” Consult your healthcare provider for medical advice.
No recalls were found on PCSK9 inhibitors. You can search the FDA database to find updates on recalls.
Do not take a PCSK9 inhibitor if you are allergic to any component of the drug.
Caution should be used with Repatha in people who are allergic to latex.
Before using a PCSK9 inhibitor, your healthcare provider will instruct you on administration. Follow your healthcare provider’s instructions and consult them with any questions or concerns. Also, be sure to follow storage requirements as described in the product labeling.
No, PCSK9 inhibitors are not controlled substances.
Common adverse effects of the PCSK9 inhibitors Praluent and Repatha include:
Common cold
Cough
Upper respiratory infection
Sinus infection
Bronchitis
Influenza
Diabetes mellitus (when used for cardiovascular prevention)
Back pain
Allergic reaction
Injection site reaction
Urinary tract infection
Headache
Muscle spasms
Muscle and/or bone pain
Dizziness
Increased blood pressure
Diarrhea
Stomach virus
Confusion
Abnormal liver function tests
Serious side effects may include:
Allergic reaction (can be common and/or severe)
Swelling beneath the skin (angioedema)
Severe skin reaction with inflamed blood vessels (hypersensitivity vasculitis)
If you are taking a PCSK9 inhibitor and experience symptoms of an allergic reaction, such as hives, rash, skin sores, blisters, difficulty breathing, or swelling of the lips, tongue, or face, seek emergency medical treatment right away.
Other adverse events may occur. Consult your healthcare professional about what side effects to expect and how to address them. You can report side effects to your doctor. You can also report side effects to the FDA by calling 1-800-FDA-1088.
Because PCSK9 inhibitors are currently only available in brand-name form, they can be quite expensive. Insurance and Medicare prescription coverage vary by plan. Contact your insurance provider for up-to-date coverage information. You can also check the manufacturer websites for Repatha or Praluent, as both manufacturers offer copay assistance programs to people who fit certain eligibility requirements.
You can always use our free discount cards and coupons when filling and refilling your PCSK9 inhibitor prescription. Using a SingleCare card can save up to 80% on prescription prices. Ask your pharmacist to compare costs and see how you can save on your prescriptions.
After receiving her doctorate from the University of Pittsburgh School of Pharmacy, Karen Berger, Pharm.D., has worked in both chain and independent community pharmacies. She currently works at an independent pharmacy in New Jersey. Dr. Berger enjoys helping patients understand medical conditions and medications—both in person as a pharmacist, and online as a medical writer and reviewer.
...(Except Major Holidays)
© 2024 SingleCare Administrators. All Rights Reserved.
* Prescription savings vary by prescription and by pharmacy, and may reach up to 80% off cash price.
Pharmacy names, logos, brands, and other trademarks are the property of their respective owners.
Pharmacy names, logos, brands, and other trademarks are the property of their respective owners.
This is a prescription discount plan. This is NOT insurance nor a Medicare prescription drug plan. The range of prescription discounts provided under this discount plan will vary depending on the prescription and pharmacy where the prescription is purchased and can be up to 80% off the cash price. You are fully responsible for paying your prescriptions at the pharmacy at the time of service, but you will be entitled to receive a discount from the pharmacy in accordance with the specific pre-negotiated discounted rate schedule. Towers Administrators LLC (operating as 'SingleCare Administrators') is the authorized prescription discount plan organization with its administrative office located at 4510 Cox Road, Suite 111, Glen Allen, VA 23060. SingleCare Services LLC ('SingleCare') is the vendor of the prescription discount plan, including their website.website at www.singlecare.com. For additional information, including an up-to-date list of pharmacies, or assistance with any problems related to this prescription drug discount plan, please contact customer service toll free at 844-234-3057, 24 hours a day, 7 days a week (except major holidays). By using the SingleCare prescription discount card or app, you agree to the SingleCare Terms and Conditions found at https://www.singlecare.com/terms-and-conditions